Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16)
- 3 August 1993
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 46 (3) , 389-393
- https://doi.org/10.1016/0006-2952(93)90514-w
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology, 1992
- Iron is the intracellular metal involved in the production of DNA damage by oxygen radicalsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1991
- Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529)Pharmacology & Therapeutics, 1990
- DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGSAnnual Review of Biochemistry, 1989
- H2O2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assaysAnalytical Biochemistry, 1988
- Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitroBiochemical Pharmacology, 1987
- Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase IIScience, 1984
- Biological Properties of ICRF-159 and Related Bis(dioxopiperazine) CompoundsPublished by Elsevier ,1982
- Reduction of daunomycin toxicity by razoxaneBritish Journal of Cancer, 1981
- Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in ehrlich ascites tumour cellsBiochemical Pharmacology, 1978